


## to cancer treatment

Peter George<sup>4</sup>, Haleigh Wood<sup>4</sup>, Ayse Tezcan<sup>4</sup>, Ram Yalamanchili<sup>4</sup>, Ken Nesmith<sup>4</sup>, John C. Spinosa<sup>4</sup>, Haluk Tezcan<sup>4,#</sup>, Young Kwang Chae<sup>1,#</sup>

patients undergoing treatment with metastatic malignancies.

survival (PFS).

clinical evaluation by a median of 34 days.



|                |       |             |    | A – (T   | 1        |
|----------------|-------|-------------|----|--|----------|
|                |       | N (28)      | %  | Types of Tl  | ור<br>וו |
| Age (years)    |       |             |    |  |          |
| Mean           | (SD)  | 68 (9.5)    |    |  |          |
| Median (Min, I | Max)  | 70 (43, 82) |    | immuno   |          |
| Sex            |       |             |    | targeted   |          |
| Fei            | male  | 19          | 68 |  |          |
|                | Male  | 9           | 32 | endocrine  |          |
| Concer Site    |       |             |    | $\begin{array}{cccc} 0 & 10 & 20 \\ 0 & 0 & 0 \end{array}$ |          |
| Cancer Site    |       |             |    | <b>C</b> % of patie  | 31       |
|                | Lung  | 13          | 47 | Baseline blood   |          |
| Bi             | reast | 11          | 39 | sample   | _        |
| C              | Other | 4           | 14 | First post-baseline<br>blood sample                        |          |
|                |       |             |    | Second post-baseline                                       |          |
| Outcome        |       |             |    | blood sample<br>First follow–up                            |          |
| Progres        | ssion | 9           | 32 | imaging  | 8        |
| No Progres     | ssion | 19          | 68 | Last<br>follow-up  |          |